Chimerix Inc. (NASDAQ:CMRX) shares were down 3.5% on Tuesday . The company traded as low as $3.90 and last traded at $3.91, with a volume of 184,893 shares changing hands. The stock had previously closed at $4.05.

A number of analysts have recently commented on CMRX shares. Zacks Investment Research raised shares of Chimerix from a “hold” rating to a “buy” rating and set a $5.25 target price for the company in a research note on Wednesday, May 11th. FBR & Co reissued a “hold” rating on shares of Chimerix in a research note on Sunday. Two research analysts have rated the stock with a sell rating, eleven have issued a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the stock. Chimerix currently has an average rating of “Hold” and a consensus price target of $16.98.

The firm’s 50-day moving average is $4.10 and its 200-day moving average is $5.57. The stock’s market cap is $181.15 million.

Chimerix (NASDAQ:CMRX) last released its earnings results on Monday, May 9th. The biopharmaceutical company reported ($0.57) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.66) by $0.09. The firm earned $1.20 million during the quarter, compared to analyst estimates of $2.79 million. Equities research analysts predict that Chimerix Inc. will post ($2.06) earnings per share for the current fiscal year.

In other news, Director Ernest Mario bought 50,000 shares of Chimerix stock in a transaction dated Friday, June 24th. The stock was bought at an average price of $3.70 per share, for a total transaction of $185,000.00. Following the purchase, the director now owns 381,440 shares of the company’s stock, valued at $1,411,328. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO M Michelle Berrey bought 13,188 shares of Chimerix stock in a transaction dated Friday, June 24th. The stock was purchased at an average price of $3.69 per share, with a total value of $48,663.72. Following the purchase, the chief executive officer now directly owns 258,821 shares in the company, valued at approximately $955,049.49. The disclosure for this purchase can be found here.

Other institutional investors recently made changes to their positions in the company. Jennison Associates LLC increased its position in shares of Chimerix by 67.9% in the fourth quarter. Jennison Associates LLC now owns 1,273,779 shares of the biopharmaceutical company’s stock worth $11,400,000 after buying an additional 515,029 shares in the last quarter. Morgan Stanley increased its position in shares of Chimerix by 96.7% in the fourth quarter. Morgan Stanley now owns 187,163 shares of the biopharmaceutical company’s stock worth $1,674,000 after buying an additional 92,005 shares in the last quarter. Finally, Trexquant Investment LP increased its position in shares of Chimerix by 453.5% in the fourth quarter. Trexquant Investment LP now owns 131,184 shares of the biopharmaceutical company’s stock worth $1,174,000 after buying an additional 107,484 shares in the last quarter.

Chimerix, Inc a biopharmaceutical company dedicated to discovering, developing and commercializing oral antivirals. The Company’s lipid conjugate technology has developed its lead compound, brincidofovir (BCV, CMX001), which is in Phase III clinical development. It is clinical-stage nucleotide analog lipid-conjugate which has demonstrated potent antiviral activity and safety in convenient, orally administered dosing regimens.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.